<DOC>
	<DOCNO>NCT01769833</DOCNO>
	<brief_summary>This study propose compare effect 48 week exposure pegylated interferon alpha vs. nucleoside analogue ( NA ) hepatitis B e antigen ( HBeAg ) seroconversion HBsAg level nucleoside analogue control HBeAg-positive chronic hepatitis B ( CHB ) patient undetectable hepatitis B virus ( HBV ) viral load least 1 year .</brief_summary>
	<brief_title>HBsAg Decline After Pegylated-interferon-α e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance</brief_title>
	<detailed_description>Pegylated interferon long term NA therapy potentiate antiviral efficacy directly via effect broad antiviral activity indirectly via activation innate adaptive immune response lead HBeAg seroconversion eventually HBsAg loss and/or seroconversion . This study propose compare effect 48 week exposure pegylated interferon alpha vs. NA HBeAg seroconversion HBsAg level NA control HBeAg-positive CHB patient undetectable HBV viral load least 1 year .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Informed consent Age 20 year HBeAgpositive CHB patient Patients treat available nucleoside analogue monotherapy combination Korea except telbivudine ( e.g.entecavir monotherapy lamivudine/adefovir combination , lamivudine , adefovir monotherapy ) ≥ 18months patient undetectable HBV viral load least one year HBV DNA undetectable ( ≤ 400 copies/ml ) Serum alanine transferase : ≤ 10 X upper limit normal ( ULN ) Baseline HBsAg : ≥ 102 IU/ml Negative urine serum pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose test drug . Additionally , fertile male partner childbearing age female must use reliable contraception study 3 month treatment completion . Obtaining write informed consent form Decompensated cirrhosis contraindication interferon alfa 2a therapy follow local label . Concomitant prior use telbivudine . Positive test screen hepatitis A virus immunoglobulin M Ab , Hepatitis C virusRNA hepatitis C virus Ab , hepatitis delta virus Ab HIV Ab . Diagnosed hepatic cellular carcinoma Any evidence decompensated liver disease ( Childs BC ) History evidence medical condition associate chronic liver disease ( e.g. , hemochromatosis , autoimmune hepatitis , alcoholic liver disease , toxin exposure , thalassemia ) . Women ongoing pregnancy breast feeding . Evidence alcohol and/or drug abuse within one year entry . History major organ transplantation exist functional graft . Inability unwillingness provide inform consent abide requirement study . History evidence severe illness condition would make patient , opinion investigator , unsuitable study . Patients value alphafetoprotein &gt; 100 ng/mL exclude , unless stability ( le 10 % increase ) document least previous 3 month . patient hypersensitivity peginterferon alfa2a NAs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>HBsAg</keyword>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>PEGinterferon Alfa-2A</keyword>
</DOC>